Ivacaftor resulted in significant improvement in lung function in CF patients with the G551D mutation and was recently approved by the U.S. Food and Drug Administration for use in individuals who are over 6 years of age and have specific mutations.(57) To date, there have been no studies examining the effects of CFTR modulators on the sinonasal mucosa. This evidence concerns the gene CFTR and cystic fibrosis.